Erik Yngve Holmer

Title: The Innovations of Erik Yngve Holmer

Introduction

Erik Yngve Holmer is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biochemistry, particularly in the development of chemically-modified heparins. With a total of four patents to his name, Holmer's work has implications for medical treatments and pharmaceutical applications.

Latest Patents

Holmer's latest patents include innovative processes for the production of chemically-modified heparins. One of his inventions relates to a process for producing heparin derivatives with an average molecular weight ranging from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg. This process involves the oxidation of unfractionated heparin, depolymerization, and reduction of the resulting terminal groups. Another significant patent focuses on low anticoagulant heparins, which are chemically modified heparins with an anti-factor II activity of less than 10 IU/mg and an average molecular weight between about 6.5 and 9.5 kDa. This invention also includes a method for preparing the heparin and its medical use, including treatment for malaria.

Career Highlights

Throughout his career, Erik Yngve Holmer has worked with various companies, including Dilafor AB and Carmeda AB. His expertise in biochemistry and innovative approaches to heparin production have positioned him as a key figure in his field.

Collaborations

Holmer has collaborated with notable colleagues such as Per-Olov Eriksson and Hans-Peter Ekre. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Erik Yngve Holmer's contributions to the field of biochemistry through his innovative patents on chemically-modified heparins highlight his importance as an inventor. His work not only advances scientific knowledge but also has practical applications in medicine.